1 Current progress and mechanisms of bone metastasis in lung cancer: a narrative review
来源:TRANSL LUNG CANCER R( P 2218-6751 E 2226-4477 ) 发表时间: 2021/01
类型:期刊论文 为本人加分:1503.245955
2 CD39: the potential target in small cell lung cancer
来源:TRANSL LUNG CANCER R( P 2218-6751 E 2226-4477 ) 发表时间: 2020/08
类型:期刊论文 为本人加分:366.142746
贡献度:共同第一作者
3 Comparison between the first-line and second-line immunotherapy drugs in the progression-free surviv..
来源:ANN PALLIAT MED( P 2224-5820 E 2224-5839 ) 发表时间: 2021/02
类型:期刊论文 为本人加分:350.450250
贡献度:单独第一作者
4 mRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer
来源:J HEALTHC ENG( P 2040-2295 E 2040-2309 ) 发表时间: 2021/09
类型:期刊论文 为本人加分:121.230387
贡献度:参与作者
5 Mechanisms of Progression and Heterogeneity in Multiple Nodules of Lung Adenocarcinoma
来源:SMALL METHODS( P 2366-9608 E ) 发表时间: 2021/06
类型:期刊论文 为本人加分:9.970355
贡献度:参与作者
6 The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
来源:TRANSL LUNG CANCER R( P 2218-6751 E 2226-4477 ) 发表时间: 2021/02
类型:期刊论文 为本人加分:9.047131
贡献度:参与作者
7 A narrative review of tumor heterogeneity and challenges to tumor drug therapy
来源:ANN TRANSL MED( P 2305-5839 E 2305-5847 ) 发表时间: 2021/08
类型:期刊论文 为本人加分:7.051522
8 FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III
来源:J IMMUNOTHER CANCER( P E 2051-1426 ) 发表时间: 2021/05
类型:期刊论文 为本人加分:2.931039
贡献度:参与作者
9 Aberrant methylation modifications reflect specific drug responses in small cell lung cancer
来源:GENOMICS( P 0888-7543 E 1089-8646 ) 发表时间: 2021/05
类型:期刊论文 为本人加分:2.887914
贡献度:参与作者
10 Risk-score model to predict prognosis of malignant airway obstruction after interventional bronchosc..
来源:TRANSL LUNG CANCER R( P 2218-6751 E 2226-4477 ) 发表时间: 2021/07
类型:期刊论文 为本人加分:2.388266
贡献度:参与作者